Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer Failing First-line Treatment.

Trial Profile

Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer Failing First-line Treatment.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Ascrinvacumab (Primary)
  • Indications Urogenital cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Nov 2015 Status changed from recruiting to discontinued as per the results published in the Investigational New Drugs.
    • 05 Oct 2013 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top